Monopar Therapeutics Inc. - MNPR STOCK NEWS

Monopar Therapeutics (NASDAQ: MNPR) reported its fourth quarter and full-year 2021 financial results and highlighted significant advancements in its clinical trials. The company is actively recruiting for the Phase 2b/3 VOICE trial of Validive, aimed at preventing severe oral mucositis in oropharyngeal cancer patients. The trial now includes 44 sites across the U.S. and Europe. Additionally, the Phase 1b trial of camsirubicin is advancing into its third dose level, with early signs of clinical benefit. Cash reserves of $20.3 million are expected to support clinical operations through March 2023.

Monopar Therapeutics (Nasdaq: MNPR) announces that CEO Chandler Robinson will present at two upcoming conferences. The 34th Annual Roth Conference is scheduled for March 14, 2022, at 1:30 PM Pacific Time, at The Ritz Carlton in Laguna Niguel, California. The Maxim’s 2022 Virtual Growth Conference will take place on March 30, 2022, at 4:30 PM Eastern Time. Monopar focuses on therapeutics aimed at improving the lives of cancer patients, with a pipeline that includes Validive® and camsirubicin.

Monopar Therapeutics Inc. (Nasdaq: MNPR) announced significant updates regarding its clinical trials. The Validive Phase 2b/3 VOICE trial is now active at 43 sites in the US and EU, focusing on preventing severe oral mucositis (SOM) in oropharyngeal cancer patients undergoing chemoradiotherapy. Additionally, early signs of clinical benefit were observed in the open-label Phase 1b trial for camsirubicin, aimed at treating advanced soft tissue sarcoma. The company is also advancing its radiopharmaceutical platform and MNPR-202 in preclinical studies.

Monopar Therapeutics Inc. (Nasdaq: MNPR), a biopharmaceutical company focused on cancer therapeutics, announced that CEO Chandler Robinson, MD, will present at the H.C. Wainwright BioConnect Conference. The presentation will be available for on-demand viewing starting January 10, 2022, at 7:00am ET.

Monopar's pipeline includes Validive® for severe oral mucositis in oropharyngeal cancer, camsirubicin for advanced soft tissue sarcoma, and other promising candidates targeting advanced cancers and COVID-19.

Monopar Therapeutics (MNPR) has received a positive recommendation from its safety review committee to escalate to the second dose level in the camsirubicin Phase 1b trial for advanced soft tissue sarcoma. This decision follows safety data review from the initial dose cohort, allowing the evaluation of a higher dose of camsirubicin.

Camsirubicin, an analog of doxorubicin, has shown potential anti-tumor activity without the severe cardiotoxicity common to doxorubicin. The trial is actively enrolling patients, with results expected to enhance treatment options for cancer patients.

Monopar Therapeutics (Nasdaq: MNPR) reported its Q3 2021 results, highlighting advancements in clinical trials. Validive, aimed at preventing severe oral mucositis, has received clearance in Europe for Phase 2b/3 trials, set to reach interim results in H1 2022. The Camsirubicin Phase 1b trial has initiated dosing, with further site activations planned. As of September 30, 2021, cash and equivalents totaled $22.3 million, expected to fund ongoing trials through December 2022. However, the net loss increased to $2.5 million from $1.6 million year-over-year.

Monopar Therapeutics Inc. (MNPR) has announced the dosing of its first patient in a Phase 1b clinical trial for camsirubicin, targeting advanced soft tissue sarcoma (ASTS). This marks a significant milestone shortly after receiving FDA approval in August 2021. The trial aims to enroll 21 patients, addressing a critical need as ASTS patients typically face a life expectancy of 12-15 months. Camsirubicin, a novel analog of doxorubicin, has previously shown promising results without the severe cardiotoxicity associated with its predecessor. Further details can be found on ClinicalTrials.gov under identifier NCT 05043649.

Monopar Therapeutics (Nasdaq: MNPR) has initiated a Phase 1b clinical trial for camsirubicin, targeting advanced soft tissue sarcoma (ASTS). This open-label study aims to assess the safety and anti-tumor efficacy of escalating doses of camsirubicin with growth factor support. Previous studies showed camsirubicin's comparable anti-tumor activity to doxorubicin without causing irreversible heart damage. The trial enrollment has been expedited due to significant interest from clinical sites, marking a critical step in the drug's development.

Monopar Therapeutics (MNPR) has received authorization to proceed with the Phase 2b/3 VOICE clinical trial in France, targeting severe oral mucositis in oropharyngeal cancer patients undergoing chemoradiotherapy. This follows the trial's initiation in the US and is positioned to expand into other European countries shortly. The upcoming ESMO Congress will feature a presentation detailing the trial's design and rationale. The company anticipates reaching the interim results by early 2022. Validive, the treatment under evaluation, has shown promising Phase 2 results, reducing mucositis incidence significantly.